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1. Introduction  
Although the understanding of disease mechanisms becomes rapidly progressed in recent 
years, there remain a lot of unmet medical needs in a number of disease fields. Especially in 
the degenerative diseases of the central nervous system (CNS) such as Alzheimer’s disease, 
Parkinson’s disease, multiple sclerosis, stroke and traumatic brain injury, currently available 
drugs only manage the symptoms, and there exist few disease-modifying therapies. 
Therefore, novel therapeutic interventions that modify and delay the disease progression are 
highly demanded. Drug development for the CNS diseases is particularly challenging (Kola 
I and Landis J, 2004). One of the hurdles to develop drugs for the CNS diseases is poor 
translation from animal models to human diseases (Pritchard JF, 2008). 
One strategy to overcome this hurdle is to examine therapeutic potential of a target 
molecule in a number of experimental settings, assuming that a molecule that modulates 
pathophysiologic mechanisms underlying a range of neurodegenerative disease has a 
higher chance to work in human disease (Mehal WZ, Iredale J & Friedman SL 2011). 
Although this strategy requires much resource, it enables us to eliminate candidates that act 
only in a particular experimental setting that might have a lower chance to be effective in 
humans. One example for this strategy is a kynurenine 3-monooxygenase that catalyzes the 
conversion of kynurenine to 3-hydroxykynurenine in the kynurenine pathway of 
tryptophan degradation (Stone TW & Darlington LG, 2002; Schwarcz R, 2004). A small 
molecule inhibitor of kynurenine 3-monooxygenase increased the levels of neuroprotective 
kynurenic acid and decreased the levels of neurotoxic quinolinic acid/3-hydroxykynurenine 
in mice. Furthermore, the treatment with the kynurenine 3-monooxygenase inhibitor 
ameliorated neurodegeneration in two types of mouse neurodegenerative models for 
Alzheimer’s disease and Huntington’s disease (Reinhart PH & Kelly JW, 2011; Zwilling D et 
al., 2011). These observations suggest that the kynurenine 3-monooxygenase would be more 
promising therapeutic target than conventional therapeutic ones that are effective in animal 
models of a single disease. 
Another strategy to increase the probability of success of drug development in the CNS 
diseases is to target a molecule that possess multiple pharmacological actions and hence 
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might affect different pathophysiological phases of the disease at once, because the CNS 
diseases often arise from multiple pathological steps and/or factors and conventional 
approaches to treat one disease phase has limited efficacy in CNS disorders. 
There are at least two types of approaches for this strategy. First one is to develop multi-
specific therapeutics, in which two or more different mechanisms of actions are given in 
one molecule. Several classical drugs are known to exhibit multiple therapeutic actions in 
a single molecular form (e.g. aspirin, thalidomide etc.), and this strategy has been 
developed in industries, especially in a field of biologics such as bi- or multi-specific 
antibodies and co-agonistic peptides (Day JW et al., 2009; Fitzgerald J & Lugovskoy A, 
2011). For example, a marketed antibody Herceptin, which targets human epidermal 
growth factor receptor 2 (HER2), was modified to have the simultaneous interaction to 
HER2 and vascular endothelial growth factor (VEGF) with high affinity in order to 
develop more efficient antibody-based therapeutics (Bostrom et al., 2009). Actually, the 
modified bi-specific antibodies inhibited the growth of both human colon cancer and 
human breast cancer in animal models, whereas an antibody mono-specific for HER2 or 
VEGF are only effective for either of them, indicating that the modified bi-specific 
antibodies are therapeutically effective for a range of types of cancers (Bostrom et al., 
2009). In addition, it is speculated that co-inhibition of HER2 and VEGF in breast cancer is 
more beneficial than single inhibition of either molecules, because tumor proliferation 
mediated by HER2 and tumor angiogenesis mediated by VEGF are expected to be 
concurrently inhibited (Bostrom et al., 2009).  Theoretically, bi- or multi-specific 
therapeutics are expected to be more effective and useful than most of mono-specific 
therapeutics. However, it is generally more difficult to develop bi- or multi-specific 
therapeutics than mono-specific therapeutics, since simultaneous optimization for 
multiple biological actions in one molecule are required. 
Second strategy is to target a single molecule that plays critical pathological roles in the 
multiple phases of the disease progression, which is consistent with our current hypothesis 
that a molecule that possesses multi-functions and hence modulates multiple 
pathophysiologic phases of a disease will be a more promising therapeutic target for 
neurodegenerative diseases than current drugs that acts only a single phase of the disease 
process. 
In recent years, we pursue the latter strategy, especially focusing on the CNS diseases that 
consist of an inflammatory/immune-mediated pathological phase and a neurodegenerative 
phase such as multiple sclerosis and spinal cord injury. Given the recent progress of 
understandings of the mutual crosstalk between the immune and the central nervous 
systems, we speculate that a number of molecules could play physiological roles in both 
immune and the central nervous systems, and some of them would be involved in the 
inflammatory/immune-mediated pathological phase and a neurodegenerative phase. 
In this chapter, we introduce our recent activities to develop novel and efficient therapeutic 
interventions by targeting a molecule that play multiple pathological roles in the 
inflammatory and degenerative phases of neurodegenerative diseases. In the following 
sections, first we briefly describe the background information and recent updates on the 
physiopathological interactions between the immune and nervous systems, and then 
illustrate the pathogenesis of the inflammatory/immune-mediated CNS diseases such as 
multiple sclerosis and spinal cord injury. Finally we introduce our efforts on a multi-
functional molecule and its therapeutic potential in neurodegenerative disease.  
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2. The mutual interactions between the immune and the nervous systems 
The CNS was previously recognized as an immune privileged site, meaning the complete 
absence of immunosurveillance within the CNS. This concept had been supported by the 
fact that the CNS is devoid of the classical lymphatic drainage and has the endothelial 
blood-brain barrier that is a tight barrier between the cerebrospinal fluids (CSF) surrounding 
the CNS parenchyma and the systemic circulation, being isolated from immune system. 
However, accumulating evidences have demonstrated that a mutual interaction between the 
immune system and central nervous system does exist both in the physiological and 
pathological situations (Steinman L, 2004; Schwartz M, 2009&2010).  
The CNS influences and controls the immune system at least partly through the autonomic 
nervous system (Steinman L, 2004). Anatomically, the autonomic nervous system via the 
vagal nerve and sympathetic nerve innervates the sites of the immune system such as 
spleen, bone marrow, thymus, lymph nodes and gastrointestinal system, and directly 
regulates the functions of the immune system. Similar to the central neural circuit where 
neurons communicate with each other via many types of neurotransmitter, the 
parasympathetic nervous pathways communicate with the immune system via the 
neurotransmitter acetylcholine, and the sympathetic nerves utilize norepinephrine as the 
neurotransmitter for the communication with the immune system. Lymphocytes express the 
receptors not only for these neurotransmitters but also for other neurotransmitters such as 
histamine, serotonin, substance P, vasoactive intestinal peptide, pituitary adenylate cyclase-
activating polypeptide and so on (Steinman L, 2004). Receptors for neuroendocrine 
mediators such as corticotrophin-releasing factor, a-melanocyte-stimulating hormone exist 
on lymphoid tissue (Steinman L, 2004). In addition, corticotrophin-releasing factor released 
by hypothalamus stimulates the secretion of ACTH from the pituitary gland, and 
consequently induces the release of glucocorticoids from the adrenal glands, which 
systemically suppress the inflammation (Sternberg, 1997). The wide variety of mediators 
enables the brain to properly coordinate the immune system and to keep the homeostasis of 
the whole body by responding to the environmental changes such as infections in an 
appropriate manner. For example, endotoxins such as lipopolysaccharide (LPS) produced 
by gram-negative bacteria activate inflammatory responses e.g. release of proinflammatory 
cytokines that are potentially lethal when overproduced. Acetylcholine, the principle vagal 
nerve transmitter, effectively suppressed LPS-induced inflammatory cytokine production. 
In addition, direct electrical stimulation of vagal nerve inhibited the in vivo shock response 
induced by LPS in rats possibly through the secretion of acetylcholine. These observations 
indicate that the brain negatively regulates systemic inflammatory responses to endotoxin 
via a parasympathetic vagal nerve pathway by limiting the inflammatory responses 
(Borovikova et al, 2000; Tracey KJ, 2002).  
In some cases, the influences of immune cells on the CNS are more manifested under 
physiological and pathological conditions. A typical example of regulation of the brain 
functions by the immune systems is the fever onset and the subsequent behavioural 
responses such as sleep, feeding and appetite (Watkins LR & Maier SF, 1999; Steinman L, 
2004). When infected with virus, bacteria and parasites, the immune system feels the danger 
to the body and releases pro-inflammatory cytokines such as interleukin 1 (IL-1), tumor 
necrosis factor (TNF) and IL-6. Regarding the fever onset, these cytokines boost the fever 
response through the neurons in the preoptic area of the hypothalamus, acting directly on 
these neurons and/or generating prostaglandin E2 (PGE2) that also regulates the fever 
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responses of these neurons (Morrison SF & Nakamura K, 2011). Consistent with the 
involvement of PGE2 in the fever response, cyclooxygenase inhibitors, which block PGE2 
production, are widely used as fever reducers. Of note, fever itself dampens the production 
of IL-1 from immune cells in the blood by modulating the proteolytic processing of this 
cytokine, again indicating the existence of the negative feedback loop that suppresses the 
overload of the inflammatory responses to keep the homeostasis of the body (Boneberg EM 
& Hartun T, 2003). 
In addition to the influences of the immune system on the CNS functions under pathological 
conditions, it has recently been hypothesized that the immune system play physiological 
roles in the maintenance of the fundamental CNS functions such as adult neurogenesis and 
spatial learning and memory (Schwartz M & Shechter R, 2010).  
Although the CNS was considered to be an immune privileged site under healthy 
conditions as mentioned above, accumulating experimental evidences have demonstrated 
that continuous leukocyte trafficking into the CNS occurs even in healthy subjects, although 
the penetration of the leukocytes is mostly observed in CSF, the choroid plexus and the 
meninges, but not in the brain parenchyma (Ransohoff RM et al., 2003; Engelhardt B & 
Ransohoff RM, 2005; Schwartz M & Shechter R, 2010). Furthermore, recent investigations 
have revealed that specialized immune cells such as resident microglia, bone marrow-
derived monocytic lineage cells, do exist in the brain parenchyma from embryonic 
developmental stage (Chan WY, 2007; Hanisch UK & Kettenmann H, 2007).  
The physiological functions of the leukocytes trafficking into the CNS have remained 
unclear. However, it has been hypothesized that these CNS-migrating leukocytes, especially 
autoimmune T lymphocytes that react with self-antigens in the CNS, contribute to the 
physiological CNS functions such as adult neurogenesis in the dentate gyrus of the 
hippocampus and spatial learning and memory (Ziv Y et al., 2006). 
In the hippocampus, an essential region for the formation of certain types of memories such 
as episodic memory and spatial memory, continuous generation of neurons is observed 
even in the adulthood, suggesting the importance of the adult hippocampal neurogenesis 
for fundamental neural functions (Deng W, 2010). With regard to the involvement of 
immune system in the hippocampus function, immune-deficient mice devoid of T cells 
(severe combined immune deficiency (SCID) mice) showed less adult neurogenesis in the 
dentate gyrus of the hippocampus compared to that in normal mice (Ziv Y et al., 2006). 
Conversely, transgenic mice engineered to produce autoimmune T cells, which react with 
the CNS antigen (myelin basic protein) and are therefore activated in the CNS, display more 
adult hippocampal neurogenesis than that in their wild-type counterparts (Ziv Y et al., 
2006). Furthermore, hippocampus-dependent spatial learning and memory was impaired in 
immune-deficient mice devoid of T cells, and was enhanced in transgenic mice with a large 
number of autoimmune T cells (Kipnis et al., 2004; Ziv Y et al., 2006). Collectively, these 
observations suggest that autoimmune T cells play critical roles in the maintenance of 
fundamental function of hippocampus through the regulation of neurogenesis. In addition, 
other groups also reported the impacts of T cells on adult hippocampal neurogenesis (Wolf 
SA et al., 2009a & 2009b; Huehnchen P et al., 2011), further supporting the concept that the 
immune system contributes to certain types of brain functions.  
On the contrary, in certain types of the degenerative CNS diseases, inflammatory and 
autoimmune responses by immune cells against the nervous system are considered to be 
harmful. Under pathological conditions such as autoimmune neurological diseases like 
multiple sclerosis and inflammatory brain/spinal cord traumatic injuries, a large number of 
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immune cells directly migrate to the CNS possibly due to the breakdown of BBB and these 
pathological infiltration of immune cells to the CNS mostly causes detrimental impact on 
the disease progression (Donnelly DJ & Popovich PG, 2008; Rezai-Zadeh K et al., 2009). 
Along with this concept, anti-inflammatory steroids and immunosuppressive therapeutic 
interventions are currently used to treat autoimmune neurological diseases and 
brain/spinal cord injuries. However, these therapies have limited clinical benefits while 
showing severe side effects (Kim Y et al., 2009; Barten LJ et al., 2010; Hilas O et al., 2010; 
Samantaray S et al., 2010). In contrast, several evidences have demonstrated that the 
immune cells rather have beneficial impacts on the pathology of the CNS diseases (Wyss-
Coray T & Mucke L, 2002; Donnelly DJ & Popovich PG, 2008). For example, the 
implantation of activated macrophages into the injured CNS exhibits therapeutic benefits 
rather than harmful actions (Lazarov-Spiegler O et al., 1996; Rapalino O et al., 1998).  
These observations suggest that the effects of the immune system on the CNS under 
pathological conditions are more complex than originally thought, depending on nature of 
pathologic mechanisms of respective disease. Development of a novel therapeutic 
intervention beyond the classical anti-inflammatory/immunosuppressive therapeutic 
approaches is essential for the treatment of these CNS diseases (Donnelly DJ & Popovich 
PG, 2008; Rezai-Zadeh K et al., 2009; Schwartz M et al., 2009).  
In the following sections, we describe more detailed characteristics of multiple sclerosis and 
spinal cord injury, especially focusing on the pathological mechanisms and discuss on 
benefits and limitations of currently available drugs and desired profiles of novel 
therapeutic interventions. 
3. The inflammatory/immune-mediated CNS diseases 
3.1 Multiple sclerosis (MS) 
Multiple sclerosis (MS) is a complex CNS disease and typically begins between age 20 and 
50. Women are affected twice more often than men, and 50% of the patients will need help 
walking within 15 years after disease onset. Its clinical symptoms include sensory and visual 
deficits, balance and gait disturbances, limb weakness, neurogenic bladder and bowel 
problems (Noseworthy JH et al., 2000). Also, in some patients, mental problems such as 
emotional liability, depression and cognitive impairment are associated.  
MS is classified into four distinct types: (1) relapsing-remitting MS; (2) secondary 
progressive MS; (3) primary progressive MS; and (4) progressive-relapsing MS 
(Noseworthy JH et al., 2000; Hilas, O et al., 2010). Approximately 80 % of the patients are 
categorized in relapsing-remitting MS, in which patients develop the symptoms over a 
period of several days, and then stabilize or even improve the symptoms within weeks. In 
some cases, neurological deficits persist after a relapse, and the disease progressively 
becomes worse between relapses (secondary progressive MS). Within 6-10 years from the 
disease onset, almost half of the patients with relapsing-remitting MS progress to 
secondary progressive MS. Twenty percent of the patients display primary progress MS 
that is characterized by a gradual and progressive disease course from the onset without 
an obvious remission stage.  
In general, this type of MS shows poor prognosis (Noseworthy JH et al., 2000; Hilas, O et al., 
2010). A fourth type of MS, referred to progressive-relapsing MS, is unusual and shows a 
progressive phenotype with obvious relapses with or without recovery. However, 
discrimination of primary progressive MS and progressive-relapsing MS on their clinical 
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characteristics is often unclear and remains controversial (Lublin FD & Reingold SC, 1996; 
Andersson PB et al., 1999). 
The precise etiology of MS remains uncertain, but it is assumed that immune responses 
against self-antigens such as myelin constituents are dysregulated in genetically susceptible 
subjects and cause destructive inflammation and autoimmune responses to the CNS 
components. This autoimmune reactions lead to demyelination and subsequent 
neurodegeneration in the CNS. Traditionally, therapeutic interventions of MS exacerbations 
in an acute phase are conducted with an anti-inflammatory steroid such as 
methylprednisolone to suppress neuroinflammation and to shorten the duration of 
exacerbation (Barten LJ, 2010). In order to reduce the frequency of relapses and slow the 
disease progression, disease-modifying drugs are also used. Current disease-modifying 
therapeutics include interferon- (IFN-) products and glatiramer acetate, which show 
modest efficacy with 30-40% reduction in MS relapse rates compared with placebo 
(Brinkmann V et al., 2010). These agents have a number of immune-related actions including 
anti-inflammatory functions, but the precise mechanisms of therapeutic actions are 
incompletely understood (Noseworthy JH et al., 2000). Although they are established first-
line therapies, they are unable to reverse existing CNS damage and have no influence on the 
development of permanent disability (Compston A & Coles A, 2002). Another marketed MS 
drug, Natalizumab is a humanized monoclonal antibody that is specific for -4 subunit of 
very late antigen 4 integrin expressed on lymphocytes. Natalizumab blocks the migration of 
leukocytes from the blood stream into the CNS across the BBB, and decreases the relapse 
rates of MS by 68% at 1 year (Polman CH et al., 2006). Despite its higher clinical efficacy 
compared to other approved therapeutics, Natalizumab is currently used only as a second-
line treatment due to its association with progressive multifocal leukoencephalopathy, 
which is a rare but life-threatening demyelinating neurological disorder caused by the 
reactivation of John Cunningham (JC) virus under immunosuppressive conditions (Barten 
LJ, 2010; Brinkmann V, 2010). Fingolimod (FTY720), an orally active drug with 
immunomodulatory actions, is recently approved as a first-line treatment for relapsing MS 
(Brinkmann V, 2010). Fingolimod influences the leukocyte trafficking through the 
modulation of sphingosine 1-phosphate receptors expressed on the leukocytes. In phase III 
trials, fingolimod demonstrated greater pharmacological efficacy in the reduction of the 
relapse rates as compared with placebo and IFN- (Cohen JA et al., 2010; Kappos L et al., 
2010). However, fingolimod treatment causes some adverse events such as infections, 
cardiovascular and ocular events in several cases, requring long-term follow-up clinical 
studies in order to provide further information on the benefit-risk profile of fingolimod as a 
novel oral treatment for relapsing MS (Brinlmann V, 2010). 
Collectively, current therapeutic interventions for MS are mainly focusing on suppression of 
the immune system; inhibition of lymphocyte activation and the blockade of leukocyte 
trafficking into the CNS. Histopathological analyses in MS patients and MS animal models 
such as autoimmune encephalomyelitis (EAE), suggest that certain subsets of CD4+ T 
lymphocytes (helper T (Th) cells) and antigen presenting cells (APCs) such as dendritic cells 
and macrophage/microglia (CNS tissue macrophage) play key roles in the pathogenesis of 
MS (Chastain EML et al., 2011). Upon encountering CNS self-antigen such as myelin 
antigen, APCs become maturated and migrate to lymph nodes where they activate antigen-
specific CD4+ T cells by presenting the CNS self-antigen (Guermonprez J et al., 2002; Bailey 
SL et al., 2007). During the activation process, CD4+ T cells differentiate into mature effector 
subsets such as Th1, Th2, Th17 and Treg cells. Direction of CD4+ T cell differentiation is at 
www.intechopen.com
Crosstalk Between the Immune and 
Central Nervous Systems with Special Reference to Drug Development 
 
371 
least partly dependent on cytokines produced by APCs (Weaver CT et al., 2006; Zhu J & 
Paul WE, 2010). Accumulating evidences suggest that Th1 and Th17 cells are involved in the 
pathogenesis of MS (Olsson T, 1992; Segal BM, 2010). Once activated, CD4+ T cells penetrate 
into the brain and spinal cord by crossing the BBB, and are re-activated by APCs located in 
the CNS, which triggers the disease induction and progression by attacking myelin 
structures of the CNS neurons (Chastain EML et al., 2011). Mild but significant clinical 
efficacy of the existing therapeutic interventions for MS via immunosuppressive actions 
supports the autoimmune-mediated onset of MS pathology.  
However, current therapeutics such as IFN- and glatiramer acetate are ineffective in 
reversing axon degeneration, another hallmark of certain types of MS such as secondary 
progressive MS (Compston A & Coles A, 2002; Bjartmar C et al., 2003).  Thus, a novel 
intervention that concurrently inhibits autoimmune reactions and neuronal damages such as 
axon degeneration is a desirable treatment for MS patients. 
3.2 Spinal cord injury 
Traumatic injuries to the adult mammalian CNS often cause serious and long-lasting 
sensory and motor problems, because the CNS shows very poor regenerative ability. One of 
the reasons for poor regenerative ability of the CNS is that the injured CNS axons following 
brain trauma and spinal cord injury show very limited regeneration in contrast to those in 
the peripheral nervous system. The lack of appropriate axon regeneration in the CNS results 
in permanent neuronal deficits such as paralysis, and the permanent neuronal deficits have 
great impacts on quality-of –life of the injured subjects. 
The pathology of the CNS injuries, particularly spinal cord injuries, has been studied at a 
molecular level in animal models, and the lack of regeneration of injured CNS axons is 
attributed, at least partly, to the CNS environment itself rather than to any intrinsic 
disability of CNS nerve fibers (Richardson et al, 1980; David and Aguayo, 1981). Among 
myelin proteins of the CNS, there exist axon outgrowth inhibitors such as Nogo, myelin-
associated glycoprotein (MAG), and oligodendrocyte-myelin glycoprotein (OMgp), which 
are suggested to inhibit the regenerative axon growth around the lesioned site after 
traumatic injury (Mueller et al, 2005; Yamashita et al, 2005; Kubo et al, 2007).  
During our effort to identify a new member of axon outgrowth inhibitors, we discovered 
that the repulsive guidance molecule a (RGMa), which is expressed in neurons and 
oligodendrocytes in the CNS, also functions as a myelin-associated neurite outgrowth 
inhibitor (Hata et al, 2006; Yamashita et al, 2007). RGMa significantly inhibited neurite 
outgrowth in cultured neurons (Hata et al, 2006; Kubo et al, 2008). Furthermore, a 
neutralizing anti-RGMa antibody exhibits therapeutic effects on rat spinal cord injury by 
enhancing spinal axon outgrowth, suggesting that RGMa plays a key pathological role in 
suppressing axon regeneration and functional recovery after spinal cord injury (Hata et al, 
2006; Yamashita et al, 2007). 
In addition to the myelin-associated proteins that inhibit axonal regeneration, immune 
components play critical roles in the recovery process of the injured CNS. Traumatic injuries 
expose the CNS directly to the immune cells by destruction of the BBB, and are followed by 
the infiltration of a variety of immune cells around the damaged sites post injury (Jones TB 
et al., 2005; Donnelly DJ & Popovich PG, 2008). Given the immune-mediated pathology of 
the CNS diseases such as MS, it had been assumed that the penetrating active immune cells 
were harmful, and therefore should be eliminated or suppressed (Popovich PG, 2000; Dheen 
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St et al., 2007). Along with this concept, anti-inflammatory steroids are currently used for the 
treatment of spinal cord injury. However, the therapeutic efficacy of steroids such as 
methylprednisolone is limited, and therefore, the original concept that the CNS 
inflammation is simply harmful is currently re-considered. 
Among the immune cells that accumulate at the lesion site, macrophages and microglia are 
reported to have both beneficial and detrimental impacts on the recovery from CNS injury 
(Jones TB et al., 2005; Donnelly DJ & Popovich PG, 2008; Popovich PG & Longbrake EE, 
2008). The beneficial role of macrophages/microglia at the lesion site is the clearance of 
debris of the damaged axon and myelin that inhibit axon regeneration, through their 
phagocytotic actions and protease secretion. The concurrent secretion of neurotrophic 
factors that promote axon elongation/neuronal survival is potentially beneficial for the 
recovery of the damaged CNS (Jones TB et al., 2005; Donnelly DJ & Popovich PG, 2008; 
Popovich PG & Longbrake EE, 2008). Of note, it was reported that the implantation of 
activated macrophages promoted axon growth and functional recovery following CNS 
injury (Lazarov-Spiegler O et al., 1996; Rapalino O et al., 1998). 
On the other hand, the excessive inflammatory responses induced by 
macrophages/microglia upon CNS injuries are detrimental to the recovery of the injured 
CNS (Jones TB et al., 2005; Donnelly DJ & Popovich PG, 2008; Popovich PG & Longbrake EE, 
2008). For example, pro-inflammatory cytokines such as TNF- and/or IL-1 expressed by 
activated macrophages/microglia enhance neuronal degeneration after spinal cord injury 
(Lee YB et al., 2000; Nesic O et al., 2001; Genovese T et al., 2006). 
These lines of evidences described above suggest that the complex crosstalk between the 
immune system and CNS exists through a variety of molecules in the 
inflammatory/immune-mediated CNS disease. Interestingly, we found that RGMa is 
expressed not only in neurons and oligodendrocytes, but also in accumulated and activated 
macrophages/microglia in the injured spinal cord, suggesting RGMa might play multi-
pathophysiological roles in the degenerative CNS disorders through neural and immune 
systems. This hypothesis prompted us to uncover the function of RGMa in the immune 
system and the involvement of this molecule in the immune-mediated degenerative CNS 
diseases.  
In the next section, we describe our recent data showing the functions of RGMa in the 
immune system and its potential involvement in the pathogenesis of one of the immune-
mediated CNS diseases, MS by using an animal model of MS, EAE. 
4. Repulsive guidance molecule a (RGMa) that has pivotal roles both in the 
CNS and the immune system is a promising drug target 
RGMa was originally discovered as an axon guidance molecule in the chick visual system 
(Stahl B et al., 1990). Recently, it was reported that RGMa regulated cephalic neural tube 
closure in mouse embryo and neuronal apoptosis (Niederkofler V et al., 2004; Matsunaga E 
et al., 2004; Yamashita T, 2007). In the pathological context, we demonstrated that RGMa 
inhibited neurite outgrowth and hindered functional recovery after spinal cord injury (Hata 
et al., 2006; Kubo T et al., 2008). While the functions of RGMa in the CNS have been well-
established, its functions in other organs have remained uncertain. As described in the 
previous section, we found that RGMa was also expressed in macrophages/microglia in the 
injured spinal cord, implying the pathological roles of RGMa in the immune system. In 
order to address this possibility, we further evaluated RGMa expression in dendritic cells, 
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which are key components to evoke the immune reactions as APCs through the activation 
and differentiation of CD4+ T cells (Weaver CT et al., 2006; Zhu J & Paul WE, 2010). We 
found that bone marrow derived dendritic cells produced RGMa upon inflammatory 
stimulation with lipopolysaccharide (LPS), suggesting the involvement of RGMa in the 
immune system, especially in the activation process of CD4+ T cells triggered by dendritic 
cells (Muramatsu R et al., 2011). The activation process of CD4+ T cells includes the 
enhancement of the adhesion property of CD4+ T cells to intercellular adhesion molecules 
such as ICAM-1. Enhanced adhesion of CD4+ T cells to intercellular adhesion molecules 
enhanced the penetration of circulating CD4+ T cells into tissues including the CNS under 
pathological conditions such as MS. Actually, in vitro exposure of CD4+ T cells to RGMa led 
to increased adhesion to ICAM-1, showing the direct activation of CD4+ T cells by RGMa. 
These data strongly suggest that RGMa, which inhibits axon regeneration in the CNS, also 
plays regulatory roles in the immune system. 
This encouraged us to further explore the pathological involvement of RGMa in the 
immune-mediated CNS disease, mouse EAE where neurodegenerative symptom was 
evoked by immunization with myelin antigens thereby dendritic cells and activated CD4+ T 
cells plays pivotal roles in its pathogenesis. Immmunohistochemical analyses demonstrated 
that RGMa expression was upregulated in dendritic cells located in spinal cords, lymph 
nodes and spleen after the induction of mouse EAE. In order to evaluate the functional 
involvement of RGMa in the pathogenesis of EAE, we produced pharmacological effects of a 
neutralizing antibody against RGMa (Hata et al., 2006). The administration of the 
neutralizing antibody significantly suppressed the pathological changes such as 
demyelination of spinal axons and the paralysis of hind limbs in association with reduction 
of immune cell infiltration into the spinal cord and decline of inflammatory cytokine (IL-2, 
IFN-, IL-17, IL-4) production from CD4+ T cells (Muramatsu R et al., 2011).In another 
mouse EAE models where neurological deficit was induced by adoptive transfer of 
activated dendritic cells that are pretreated with CNS myelin antigens in vitro, adoptive 
transfer of the activated dendritic cells lacking RGMa caused less severe neurological deficit 
, further suggesting the pathological role of RGMa in mouse EAE. Moreover, we found that 
expression levels of RGMa in dendritic cells increased in the brain and spinal cord of human 
subjects with MS. Moreover, the blockade of RGMa with the neutralizing antibody against 
RGMa inhibited the proliferation and the inflammatory cytokine (IL-2, IFN-, IL-17A, IL-4) 
production by peripheral blood mononuclear cells obtained from MS patients (Muramatsu 
R et al., 2011). These observations suggest that dendritic cell-derived RGMa also plays a key 
role in T cell activation in MS subjects. Intriguingly, RGMa polymorphisms are associated 
with MS and levels of pro-inflammatory cytokines (IFN- and TNF) in CSF of MS patients 
(Nohra, R et al., 2010). Collectively, these lines of evidences strongly suggest that RGMa 
plays critical roles in the pathogenesis of MS, especially via activating autoreactive CD4+ T 
cells (Muramatsu et al., 2011; Flemming A, 2011). 
In the current experimental settings where the neutralizing antibody to RGMa was 
administered via a peripheral route, the therapeutic benefits of RGMa inhibition is assumed 
to be mainly based on the blockade of the immune system i.e. reduction of the penetration of 
immune cells such as activated CD4+ T cells from circulation into CNS, since the antibody 
did not effectively reach to the CNS (Muramatsu R et al., 2011). Nevertheless, we could not 
exclude the possibility that the therapeutic effect of anti-RGMa antibodies was partially 
mediated by the therapeutic action on the CNS because a small amount, but significant 
levels of the antibodies were detected in the spinal cord.  
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Current therapeutic interventions for MS mainly focus on anti-inflammatory effects and 
they are ineffective in reversing the CNS damage (Noseworthy JH et al., 2000; Compston A 
& Coles A, 2002; Bjartmar C et al., 2003).The approach to inhibit RGMa, an endogenous axon 
regrowth inhibitor, might enhance the recovery of neuronal deficits not only by suppressing 
excessive autoimmune responses but also by promoting regeneration of the damaged axons 
and restoration of the injured neural circuit in EAE.  However, the pathological actions of 
RGMa on the axon damage in the CNS are needed to be further addressed in EAE. 
Other molecules that are originally identified as regulatory factors in the CNS are also 
reported to have key roles in the pathogenesis of the inflammatory/immune-mediated 
diseases. For example, semaphorins that regulate axon guidance during neural development 
are reported to directly modulate the immune reactions in animal disease models including 
EAE (Suzuki K et al., 2008; Kumanogoh A & Kikutani H, 2010). This further supports the 
idea to target a molecule that acts both in the inflammatory/immune-mediated pathological 
phase and a neurodegenerative phase in the neurodegenerative diseases. 
A therapy with a neutralizing antibody provides a highly target-selective intervention, but 
is also associated with critical drawbacks such as poor exposure to the CNS as mentioned 
and parenteral route administration. Identification of a small molecule drug that mimics 
antibody and interferes directly with the ligand-receptor interaction or subsequent signal 
transductions is an alternative strategy to overcome the drawbacks of therapeutic 
antibodies. However, development of a small compound that blocks direct interactions of 
large proteins often encounters high hurdles. In this context, we identified a key signal 
pathway that mediates the inhibitory action of RGMa on neurite outgrowth (Hata K et al., 
2006; Kubo T et al., 2008). RGMa expresses its actions through the receptor, neogenin and its 
inhibitory actions are mediated by the downstream effectors, Rho, Rho kinase and myosin 
IIA. Therefore, small molecule that inhibits the actions of downstream molecules (Rho, Rho 
kinase and myosin IIA) would be alternative approaches to the therapeutic antibodies. Since 
inhibitors for Rho, Rho kinase and myosin IIA are currently available, it is worth examining 
their therapeutic potentials on EAE and spinal cord injury (Straight AF et al., 2003; Mueller 
BK et al., 2005; Kubo T & Yamashita T, 2007). Actually, fasudil, a Rho kinase inhibitor, 
exhibits therapeutic effects on experimental spinal cord injury, supporting the strategy to 
block downstream signals of a target molecule for the treatment of the 
inflammatory/immune-mediated neurodegenerative diseases (Hara M et al., 2000; Sung JK 
et al., 2003; Ding J et al., 2010). 
5. Conclusion 
In this chapter, we illustrate our recent strategy to develop a novel and effective therapeutic 
interventions, especially focusing on the identification of potential targets that have multiple 
pathophysiological functions in the neurodegenerative diseases such as MS and spinal cord 
injury. Our recent efforts to discover a molecule that displays multiple actions in the 
immune system and the CNS resulted in the identification of RGMa that plays a key role in 
the autoimmune-mediated pathological process in the CNS disease. Furthermore, 
therapeutic potential of RGMa inhibitor is demonstrated by the pharmacological benefits of 
the anti-RGMa neutralizing antibody in EAE animal model. Although the central effects of 
the neutralizing antibody has remained to be addressed, current experimental data suggest 
that the blockade of RGMa functions might provide improved therapeutic effects on 
autoimmune encephalomyelitis through the inhibition of harmful autoimmune reactions 
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and the promotion of axon regeneration of damaged neurons (Figure 1). In addition, the 
effectiveness of a small molecule inhibitor of the downstream signal pathway suggests the 
alternative drug discovery approach with higher probability of success. 
This type of strategy to target a single molecule with multiple pathological actions will give 
us an opportunity to develop an efficient therapeutic intervention, which will be further 
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Fig. 1. RGMa plays key pathological roles both in the activation of autoreactive CD4+ T cells 
and the inhibition of regeneration of damaged CNS axons, which renders RGMa as a 
promising drug target for the treatment of inflammatory/immune-mediated CNS diseases. 
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